Vanguard Group Inc Aravive, Inc. Transaction History

Vanguard Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.11 - $0.22 $4,928 - $9,857	-44,806 Reduced 3.93%	1,094,695 $131,000
Q3 2023 Nov 14, 2023	SELL	$0.11 - $1.76 $48,836 - $781,390	-443,972 Reduced 28.04%	1,139,501 $148,000
Q2 2023 Aug 14, 2023	SELL	$1.25 - $1.92 $1.32 Million - $2.02 Million	-1,053,406 Reduced 39.95%	1,583,473 $2 Million
Q1 2023 May 15, 2023	BUY	$1.29 - $2.46 $2.85 Million - $5.44 Million	2,212,724 Added 521.68%	2,636,879 $5.27 Million
Q4 2022 Feb 10, 2023	BUY	$1.2 - $1.83 $362 - $552	302 Added 0.07%	424,155 $559,000

Q3 2022 Nov 14, 2022	SELL	$0.61 - $1.03 $20,353 - $34,368	-33,367 Reduced 7.3%	423,853 $346,000
Q1 2022 May 13, 2022	SELL	$1.85 - $2.75 $116,592 - $173,313	-63,023 Reduced 12.11%	457,220 $882,000
Q4 2021 Feb 14, 2022	SELL	$2.19 - $4.07 $26,227 - $48,742	-11,976 Reduced 2.25%	520,243 $1.14 Million
Q3 2021 Nov 12, 2021	BUY	$3.67 - $5.8 $39,991 - $63,202	10,897 Added 2.09%	532,219 $1.98 Million
Q2 2021 Aug 13, 2021	BUY	$4.65 - $6.42 $2.42 Million - $3.35 Million	521,322 New	521,322 $3.12 Million

1.93M

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.